Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)

John F. DiPersio, Guenther Koehne, Nirali N. Shah, Lea Bernard, Hyung C Suh, Divya Koura, Miguel Angel Perales, Roni Tamari, Muhammad Umair Mushtaq, Joseph E. Maakaron, Michael R. Loken, Darren A Stanizzi, Melissa M. Lee-Sundlov, Sanjana Thosar, Sharon L Hyzy, Glen D Raffel, Brenda W Cooper

Blood (2024) 144 (Supplement 1): 2873.

https://doi.org/10.1182/blood-2024-205641

Published: 2024

Journal Articles

Identification of Interstitial Loss of Heterozygosity (LOH) Regions Flanking CD33 Locus in AML Patients

Vivek M. Shastri, Francisco Marchi, Michael R. Loken, Jatinder K. Lamba

Blood (2024) 144 (Supplement 1): 1543.

https://doi.org/10.1182/blood-2024-211258

Published: 2024

Journal Articles

Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children's Oncology Group

Johann K. Hitzler, Todd A. Alonzo, Robert Gerbing, Jim Wang, Amy Beckman, Betsy Hirsch, Susana C. Raimondi, Karen M Chisholm, Shelton A. Viola, Anupam Verma, Lisa Eidenschink Brodersen, Michael R. Loken, Jeffrey W. Taub, Alan S Gamis, E. Anders Kolb, Todd M Cooper, Jason N. Berman

Blood (2024) 144 (Supplement 1): 2949.

https://doi.org/10.1182/blood-2024-202621

Published: 2024

Journal Articles

A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO - a Report from the Children's Oncology Group

Blood (2024) 144 (Supplement 1): 967.

https://doi.org/10.1182/blood-2024-205666

Published: 2024

Journal Articles

Preclinical Efficacy of CD276 (B7-H3) CAR T in Acute Myeloid Leukemia

Isabel Lira, Danielle C. Kirkey, Marilena Nicolaidou, Henrike Muller, Marta Barisa, Melia Blankenfeld, Grace Hawkins, Cyd McKay, Christina Root, Laura Pardo, Michael R. Loken, Tiffany Hylkema, Concetta Quintarelli, Franco Locatelli, John Anderson, Soheil Meshinchi

Blood (2024) 144 (Supplement 1): 4793.

https://doi.org/10.1182/blood-2024-206227

Published: 2024

Journal Articles

Discovery and Immunotherapeutic Targeting of the Tumor-Specific Target LAMP5 in Acute Myeloid Leukemia

Grace Hawkins, Danielle Kirkey, Nika Panahi, Melia Blankenfeld, Isabel Lira, Tiffany Hylkema, Cyd McKay, Christina Root, Jack H. Peplinski, Logan K. Wallace, Rhonda E. Ries, Laura Pardo, Michael R. Loken, Soheil Meshinchi

Blood (2024) 144 (Supplement 1): 3413.

https://doi.org/10.1182/blood-2024-204043

Published: 2024

Journal Articles

Fusion-harboring mast cells can explain molecular positivity in flow cytometric MRD-negative core-binding factor AML

Jacqueline A. Cook, Loren Lott, Jenna Perry, Ashley M. Eckel, Dongbin Xu, Chad A. Hudson, Denise A. Wells, Michael R. Loken, Andrew J. Menssen

Blood (2024) 144 (5): 581–585.

https://doi.org/10.1182/blood.2024024264

Published: 2024

Includes: Supplemental data

Journal Articles

Residual Mast Cells Can Explain Persistent Molecular Positivity in Difference from Normal Flow Cytometric-Defined MRD Negative Core Binding Factor AML

Jacqueline A. Cook, Loren Lott, Jenna Perry, Arun Nalla, Dongbin Xu, Chad A. Hudson, Denise A. Wells, Michael R. Loken, Andrew J. Menssen

Blood (2023) 142 (Supplement 1): 426.

https://doi.org/10.1182/blood-2023-180275

Published: 2023

Journal Articles

Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)

John DiPersio, Brenda W Cooper, Hyung C Suh, Divya Koura, Lea Bernard, Nirali N. Shah, Roland B. Walter, Miguel-Angel Perales, Markus Mapara, Roni Tamari, Michael R. Loken, Kyle Breitschwerdt, Sritama Nath, Glen D Raffel, Guenther Koehne

Blood (2023) 142 (Supplement 1): 483.

https://doi.org/10.1182/blood-2023-190037

Published: 2023

Journal Articles

Final Results of Phase I/II Trial of Mitoxantrone in Combination with Clofarabine (MITCL) in Children with Relapsed/Refractory Acute Leukemia

Jessica C Hochberg, Javier Oesterheld, Aliza Gardenswartz, Liana Klejmont, Jaclyn Basso, Elizabeth Mintzer, Lauren Harrison, Michael J Borowitz, Michael R. Loken, Mitchell S Cairo

Blood (2022) 140 (Supplement 1): 6140–6141.

https://doi.org/10.1182/blood-2022-167040

Published: 2022

Journal Articles

CXCR4 (CD184) Expression in Pediatric AML Is Associated with Bone Marrow Retention, Specific Disease Characteristics, and Worse Outcomes: A Report of 1004 Patients from the Children's Oncology Group AAML1031 Protocol

Andrew J. Menssen, Chad A. Hudson, Todd A. Alonzo, Robert B. Gerbing, Laura Pardo, Fan-Chi Hsu, Loren L. Lott, Fangyan Dai, Keely Ghiradelli, Yi-Cheng Wang, E. Anders Kolb, Todd M. Cooper, Jessica A. Pollard, Michael R. Loken, Richard Aplenc, Lisa Eidenschink Brodersen, Soheil Meshinchi

Blood (2022) 140 (Supplement 1): 3452–3453.

https://doi.org/10.1182/blood-2022-163682

Published: 2022

Journal Articles

Project Stella: Development and Preclinical Assessment of FOLR1-Directed Chimeric Antigen Receptor T Cells in CBF2AT3-GLIS2/RAM AML

Quy Le, Sommer Castro, Thao T. Tang, Cynthia Nourigat-Mckay, LaKeisha Perkins, Tiffany A. Hylkema, Laura Pardo, Jenny L. Smith, Amanda R. Leonti, Rhonda E. Ries, Lisa Eidenschink Brodersen, Michael R. Loken, Soheil Meshinchi

Blood (2021) 138 (Supplement 1): 2788.

https://doi.org/10.1182/blood-2021-151836

Published: 2021

Journal Articles

Therapeutic Targeting of CD74 with STRO-001 Antibody-Drug Conjugate in AML and ALL

Quy Le, Amanda R. Leonti, Thao T. Tang, Sommer Castro, Cynthia Nourigat-Mckay, LaKeisha Perkins, Rhonda E. Ries, Jenny L. Smith, Tiffany A. Hylkema, Laura Pardo, Cristina Abrahams, Kristin Bedard, Arturo Molina, Lisa Eidenschink Brodersen, Michael R. Loken, Soheil Meshinchi

Blood (2021) 138 (Supplement 1): 509.

https://doi.org/10.1182/blood-2021-151160

Published: 2021

Journal Articles

Increased Expression of CD56 on Plasmacytoid Dendritic Cells in Myeloid Leukemia Associated with Down Syndrome (ML-DS) Is Normal Regeneration and Not Measurable Residual Disease

Chad A Hudson, Laura Pardo, Loren L. Lott, Michael R. Loken, Lisa Eidenschink Brodersen

Blood (2021) 138 (Supplement 1): 3433.

https://doi.org/10.1182/blood-2021-149873

Published: 2021

Journal Articles

Epigenetic Silencing of CD34 in AML and Association with Outcome in KMT2A Fusions

Rhonda E. Ries, Lisa Eidenschink Brodersen, Laura Pardo, Timothy Junius Triche, Jr., Amanda R. Leonti, Jenny L. Smith, Todd A. Alonzo, Jason E Farrar, Yi-Cheng Wang, Alice Dang, Alan S. Gamis, Richard Aplenc, E. Anders Kolb, Michael R. Loken, Soheil Meshinchi

Blood (2021) 138 (Supplement 1): 802.

https://doi.org/10.1182/blood-2021-149210

Published: 2021

Journal Articles

Endothelial Cell Niche Promotes Leukemic Transformation of Human Cord Blood Stem/Progenitor Cells Expressing CBFA2T3-GLIS2 Oncogenic Fusion

Quy Le, Tiffany A. Hylkema, Sommer Castro, Jenny L. Smith, Amanda R. Leonti, Thao T. Tang, Cynthia Nourigat-Mckay, LaKeisha Perkins, Laura Pardo, Lisa Eidenschink Brodersen, Michael R. Loken, Rhonda E. Ries, Keith R. Loeb, Soheil Meshinchi

Blood (2021) 138 (Supplement 1): 360.

https://doi.org/10.1182/blood-2021-148916

Published: 2021

Journal Articles

Targeting FOLR1 in High-Risk CBF2AT3-GLIS2 AML with Stro-002 FOLR1-Directed Antibody-Drug Conjugate

Quy Le, Jenny L. Smith, Thao T. Tang, Sommer Castro, Cynthia Nourigat-Mckay, LaKeisha Perkins, Benjamin J. Huang, Rhonda E. Ries, Amanda R. Leonti, Tiffany A. Hylkema, Laura Pardo, Cristina Abrahams, Kristin Bedard, Arturo Molina, Lisa Eidenschink Brodersen, Michael R. Loken, Soheil Meshinchi

Blood (2021) 138 (Supplement 1): 209.

https://doi.org/10.1182/blood-2021-153076

Published: 2021

Journal Articles

CEBPA -bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children’s Oncology Group

Katherine Tarlock, Adam J. Lamble, Yi-Cheng Wang, Robert B. Gerbing, Rhonda E. Ries, Michael R. Loken, Lisa Eidenschink Brodersen, Laura Pardo, Amanda Leonti, Jenny L. Smith, Tiffany A. Hylkema, William G. Woods, Todd M. Cooper, E. Anders Kolb, Alan S. Gamis, Richard Aplenc, Todd A. Alonzo, Soheil Meshinchi

Blood (2021) 138 (13): 1137–1147.

https://doi.org/10.1182/blood.2020009652

Published: 2021

Includes: Supplemental data

Journal Articles

Therapeutic Targeting of Mesothelin in Acute Myeloid Leukemia with Chimeric Antigen Receptor T Cell Therapy

Quy Le, PhD, Sommer Castro, BS, Thao T. Tang, Anisha Loeb, BA, Amanda R. Leonti, MS, Laura Pardo, Michael R. Loken, PhD, Colin Correnti, PhD, Soheil Meshinchi, MDPhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-143140

Published: 2020

Journal Articles

Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol

Lisa Eidenschink Brodersen, PhD, Chad A. Hudson, MDPhD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Laura Pardo, Amanda R. Leonti, MS, Timothy P. Singleton, MD, Fan-Chi Hsu, PhD, Loren L. Lott, Fangyan Dai, Keely Ghiradelli, E. Anders Kolb, MD, Todd M. Cooper, DO, Jessica A. Pollard, MD, Michael R. Loken, PhD, Richard Aplenc, MD PhD, Soheil Meshinchi, MDPhD

Blood (2020) 136 (Supplement 1): 39.

https://doi.org/10.1182/blood-2020-142659

Published: 2020

NARROW

A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)

Identification of Interstitial Loss of Heterozygosity (LOH) Regions Flanking CD33 Locus in AML Patients

Treatment Intensification Does Not Improve Outcome for Children with Myeloid Leukemia of Down Syndrome (ML-DS) Who Are MRD-Positive after Induction Therapy: A Report from the Children's Oncology Group

A Phase 3 Randomized Trial for Patients with De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO - a Report from the Children's Oncology Group

Preclinical Efficacy of CD276 (B7-H3) CAR T in Acute Myeloid Leukemia

Discovery and Immunotherapeutic Targeting of the Tumor-Specific Target LAMP5 in Acute Myeloid Leukemia

Fusion-harboring mast cells can explain molecular positivity in flow cytometric MRD-negative core-binding factor AML

Residual Mast Cells Can Explain Persistent Molecular Positivity in Difference from Normal Flow Cytometric-Defined MRD Negative Core Binding Factor AML

Final Results of Phase I/II Trial of Mitoxantrone in Combination with Clofarabine (MITCL) in Children with Relapsed/Refractory Acute Leukemia

CXCR4 (CD184) Expression in Pediatric AML Is Associated with Bone Marrow Retention, Specific Disease Characteristics, and Worse Outcomes: A Report of 1004 Patients from the Children's Oncology Group AAML1031 Protocol

Project Stella: Development and Preclinical Assessment of FOLR1-Directed Chimeric Antigen Receptor T Cells in CBF2AT3-GLIS2/RAM AML

Therapeutic Targeting of CD74 with STRO-001 Antibody-Drug Conjugate in AML and ALL

Increased Expression of CD56 on Plasmacytoid Dendritic Cells in Myeloid Leukemia Associated with Down Syndrome (ML-DS) Is Normal Regeneration and Not Measurable Residual Disease

Epigenetic Silencing of CD34 in AML and Association with Outcome in KMT2A Fusions

Endothelial Cell Niche Promotes Leukemic Transformation of Human Cord Blood Stem/Progenitor Cells Expressing CBFA2T3-GLIS2 Oncogenic Fusion

Targeting FOLR1 in High-Risk CBF2AT3-GLIS2 AML with Stro-002 FOLR1-Directed Antibody-Drug Conjugate

CEBPA -bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children’s Oncology Group

Therapeutic Targeting of Mesothelin in Acute Myeloid Leukemia with Chimeric Antigen Receptor T Cell Therapy

Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only